Latest Stories
Timken (NYSE:TKR) Reports Bullish Q4 CY2025
Industrial component provider Timken (NYSE:TKR) reported revenue ahead of Wall Streets expectations in Q4 CY2025, with sales up 3.5% year on year to $1.11 billion. Its non-GAAP profit of $1.14 per share was 4.9% above analysts’ consensus estimates.
Avery Dennison (NYSE:AVY) Reports Sales Below Analyst Estimates In Q4 CY2025 Earnings
Adhesive manufacturing company Avery Dennison (NYSE:AVY) missed Wall Street’s revenue expectations in Q4 CY2025 as sales rose 3.9% year on year to $2.27 billion. Its non-GAAP profit of $2.45 per share was 2.9% above analysts’ consensus estimates.
Kennametal (NYSE:KMT) Surprises With Q4 CY2025 Sales
Industrial materials and tools company Kennametal (NYSE:KMT) announced better-than-expected revenue in Q4 CY2025, with sales up 9.8% year on year to $529.5 million. Guidance for next quarter’s revenue was optimistic at $555 million at the midpoint, 2.2% above analysts’ estimates. Its non-GAAP profit of $0.47 per share was 24.3% above analysts’ consensus estimates.
Evercore’s (NYSE:EVR) Q4 CY2025: Strong Sales
Investment banking firm Evercore (NYSE:EVR) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 31.4% year on year to $1.29 billion. Its non-GAAP profit of $5.13 per share was 26.7% above analysts’ consensus estimates.
Eli Lilly (NYSE:LLY) Reports Strong Q4 CY2025, Stock Soars
Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 42.6% year on year to $19.29 billion. The company’s full-year revenue guidance of $81.5 billion at the midpoint came in 5.1% above analysts’ estimates. Its non-GAAP profit of $7.54 per share was 8.7% above analysts’ consensus estimates.
Cencora (NYSE:COR) Misses Q4 CY2025 Revenue Estimates
Healthcare distributor Cencora (NYSE:COR) missed Wall Street’s revenue expectations in Q4 CY2025, but sales rose 5.5% year on year to $85.93 billion. Its non-GAAP profit of $4.08 per share was 1% above analysts’ consensus estimates.
Equifax (NYSE:EFX) Exceeds Q4 CY2025 Expectations
Credit reporting giant Equifax (NYSE:EFX) announced better-than-expected revenue in Q4 CY2025, with sales up 9.2% year on year to $1.55 billion. Guidance for next quarter’s revenue was optimistic at $1.61 billion at the midpoint, 2.5% above analysts’ estimates. Its non-GAAP profit of $2.09 per share was 1.8% above analysts’ consensus estimates.
Boston Scientific (NYSE:BSX) Reports Q4 CY2025 In Line With Expectations
Medical device company Boston Scientific (NYSE:BSX) met Wall Streets revenue expectations in Q4 CY2025, with sales up 15.9% year on year to $5.29 billion. The company expects next quarter’s revenue to be around $5.19 billion, close to analysts’ estimates. Its non-GAAP profit of $0.80 per share was 2.4% above analysts’ consensus estimates.
Bio-Techne (NASDAQ:TECH) Surprises With Q4 CY2025 Sales
Life sciences company Bio-Techne (NASDAQ:TECH) reported Q4 CY2025 results topping the market’s revenue expectations, but sales were flat year on year at $295.9 million. Its non-GAAP profit of $0.46 per share was 5.8% above analysts’ consensus estimates.
GE HealthCare’s (NASDAQ:GEHC) Q4 CY2025: Beats On Revenue
Healthcare technology company GE HealthCare Technologies (NASDAQ:GEHC) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 7.1% year on year to $5.70 billion. Its non-GAAP profit of $1.44 per share was 3% above analysts’ consensus estimates.